Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistanceLATAILLADE, Max; CHIARELLA, Jennifer; KOZAL, Michael J et al.Antiviral therapy (London). 2007, Vol 12, Num 4, pp 563-570, issn 1359-6535, 8 p.Article

Prevalence of low-level HIV-1 variants with reverse transcriptase mutation K65R and the effect of antiretroviral drug exposure on variant levelsKOZAL, Michael J; CHIARELLA, Jennifer; ST JOHN, Elizabeth P et al.Antiviral therapy (London). 2011, Vol 16, Num 6, pp 925-929, issn 1359-6535, 5 p.Article

HIV drug resistance and HIV transmission risk behaviors among active injection drug usersKOZAL, Michael J; AMICO, K. Rivet; CHIARELLA, Jennifer et al.Journal of acquired immune deficiency syndromes (1999). 2005, Vol 40, Num 1, pp 106-109, issn 1525-4135, 4 p.Article

Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failureLI, Jonathan Z; PAREDES, Roger; RIBAUDO, Heather J et al.AIDS (London). 2012, Vol 26, Num 2, pp 185-192, issn 0269-9370, 8 p.Article

Prevalence and impact of HIV-1 protease codon 33 mutations and polymorphisms in treatment-naive and treatment-experienced patientsKOZAL, Michael J; HUPPLER HULLSIEK, Katherine; LEDUC, Robert et al.Antiviral therapy (London). 2006, Vol 11, Num 4, pp 457-463, issn 1359-6535, 7 p.Article

Low-Abundance Drug-Resistant Viral Variants in Chronically HIV-Infected, Antiretroviral Treatment-Naive Patients Significantly Impact Treatment OutcomesSIMEN, Birgitte B; FREDRIK SIMONS, Jan; DESANY, Brian et al.The Journal of infectious diseases. 2009, Vol 199, Num 5, pp 693-701, issn 0022-1899, 9 p.Article

Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapiesBRAITHWAITE, R. Scott; KOZAL, Michael J; CHANG, Chung Chou H et al.AIDS (London). 2007, Vol 21, Num 12, pp 1579-1589, issn 0269-9370, 11 p.Article

Directly Administered Antiretroviral Therapy for HIV-Infected Drug Users Does Not Have an Impact on Antiretroviral Resistance : Results From a Randomized Controlled TrialMARU, Duncan Smith-Rohrberg; KOZAL, Michael J; BRUCE, R. Douglas et al.Journal of acquired immune deficiency syndromes (1999). 2007, Vol 46, Num 5, pp 555-563, issn 1525-4135, 9 p.Article

Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure: A Systematic Review and Pooled AnalysisLI, Jonathan Z; PAREDES, Roger; THIEBAUT, Rodolphe et al.JAMA, the journal of the American Medical Association. 2011, Vol 305, Num 13, pp 1327-1335, issn 0098-7484, 9 p.Article

A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study) : a long-term randomised trial. CommentaryABGRALL, Sophie; MACARTHUR, Rodger D; SCHMETTER, Barry et al.Lancet (British edition). 2006, Vol 368, Num 9553, issn 0140-6736, 2107-2109,2125-2135 [14 p.]Article

Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical careKOZAL, Michael J; AMICO, K. Rivet; CHIARELLA, Jennifer et al.AIDS (London). 2004, Vol 18, Num 16, pp 2185-2189, issn 0269-9370, 5 p.Article

Impact of Minority Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Resistance Genotype After Virologic FailureLI, Jonathan Z; PAREDES, Roger; OSTERGAARD, Lars et al.The Journal of infectious diseases. 2013, Vol 207, Num 6, pp 893-897, issn 0022-1899, 5 p.Article

Attitudes toward needle-sharing and HIV transmission risk behavior among HIV + injection drug users in clinical careNORTON, Wynne E; RIVET AMICO, K; FISHER, William A et al.AIDS Care (Print). 2008, Vol 20, Num 4, pp 462-469, issn 0954-0121, 8 p.Conference Paper